Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
The bill amends Section 351(k) of the Public Health Service Act governing biosimilar licensure. It removes any automatic requirement that clinical studies for biosimilarity include immunogenicity, pharmacodynamics, or comparative clinical efficacy assessments.
Left emphasizes patient safety and routine immunogenicity data
Relative to its intended legislative type, this bill is a narrowly focused substantive statutory amendment that is precise in the legal text and integration with existing law.
The bill amends Section 351(k) of the Public Health Service Act governing biosimilar licensure.
It removes any automatic requirement that clinical studies for biosimilarity include immunogenicity, pharmacodynamics, or comparative clinical efficacy assessments.
The FDA (Secretary) may still require those assessments but only at the Secretary's discretion and only if the applicant is given written notice and justification by the earliest date the applicant may file.
Technically narrow but touches safety and FDA discretion; possible stakeholder opposition and need for broader compromise lower standalone prospects.
Relative to its intended legislative type, this bill is a narrowly focused substantive statutory amendment that is precise in the legal text and integration with existing law. It clearly identifies the statutory language to change and includes a limited implementation path and a minimal accountability requirement (notice and written justification).
Left emphasizes patient safety and routine immunogenicity data
These are examples from the analysis, not a ranked list of the most-affected groups.
Left emphasizes patient safety and routine immunogenicity data
Cautious support with reservation.
The persona likes measures that can lower drug costs and increase access but worries about patient safety and robust evidentiary standards for biologics.
Pragmatic conditional support.
Sees potential efficiency and cost benefits but emphasizes safeguards, predictability, and evidence that patient safety won't be compromised.
Generally supportive.
Views the bill as sensible deregulation that reduces unnecessary testing, lowers barriers to competition, and accelerates market-based price reductions.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Technically narrow but touches safety and FDA discretion; possible stakeholder opposition and need for broader compromise lower standalone prospects.
The bill has not accumulated any surfaced votes yet.
Left emphasizes patient safety and routine immunogenicity data
Technically narrow but touches safety and FDA discretion; possible stakeholder opposition and need for broader compromise lower standalone…
Relative to its intended legislative type, this bill is a narrowly focused substantive statutory amendment that is precise in the legal text and integration with existing law. It clearly identifies the statutory languag…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.